Showing results (21-30 of 101) with videos related to
Sort By:
Pageof 11
Current Opinion in Investigational Drugs (London, England : 2000)|March 27, 2004
AIDSVAX VaxGenAndreas BillichCurrent Opinion in Investigational Drugs (London, England : 2000)|April 3, 2003
S-1360 Shionogi-GlaxoSmithKlineAndreas BillichCurrent Opinion in Investigational Drugs (London, England : 2000)|April 3, 2003
HPV vaccine MedImmune/GlaxoSmithKlineAndreas BillichAnalytical Biochemistry|February 11, 2004
Fluorescence-based assay of sphingosine kinasesAndreas Billich, Peter EttmayerSub-Cellular Biochemistry|August 30, 2008
Sphingolipid metabolizing enzymes as novel therapeutic targetsAndreas Billich, Thomas BaumrukerBioorganic & Medicinal Chemistry Letters|September 3, 2004
Estrone formate: a novel type of irreversible inhibitor of human steroid sulfataseErwin P Schreiner, Andreas BillichChemmedchem|May 1, 2015
Medicinal Chemists of the 21(st) Century--Who Are We and Where to Go?Peter NussbaumerExpert Opinion on Investigational Drugs|February 17, 2007
FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosisThomas Baumruker, Andreas Billich, Volker BrinkmannImmunology Letters|December 9, 2004
The role of sphingosine and ceramide kinases in inflammatory responsesThomas Baumruker, Frédéric Bornancin, Andreas BillichInternational Journal of Pharmaceutics|December 31, 2003
Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimusAndreas Billich, Heinrich Aschauer, András Aszódi, et al.Pageof 11